Pfizer (PFE) Accumulated Expenses (2009 - 2026)

Pfizer (PFE) has reported Accumulated Expenses for 18 consecutive years, with $2.6 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accumulated Expenses rose 4.37% year-over-year to $2.6 billion in Q2 2026; TTM through Jun 2026 was $2.6 billion, a 4.37% increase from a year earlier, with the FY2025 full-year figure at $3.6 billion, down 5.94% from the prior year.
• Accumulated Expenses was $2.6 billion for Q2 2026 at Pfizer, down from $2.7 billion in the prior quarter.
• Over five years, Accumulated Expenses peaked at $3.8 billion in Q4 2024 and troughed at $2.0 billion in Q3 2023.
• A 5-year average of $2.7 billion and a median of $2.6 billion in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses fell 18.52% in 2023 and surged 38.26% in 2024, its largest moves.
• Over 5 years, Accumulated Expenses stood at $3.4 billion in 2022, then decreased by 18.52% to $2.8 billion in 2023, then jumped by 38.26% to $3.8 billion in 2024, then dropped by 5.94% to $3.6 billion in 2025, then dropped by 29.25% to $2.6 billion in 2026.
• The last three Accumulated Expenses figures came in at $2.6 billion (Q2 2026), $2.7 billion (Q1 2026), and $3.6 billion (Q4 2025), per Business Quant data.